ES2571028T3 - Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso - Google Patents

Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso

Info

Publication number
ES2571028T3
ES2571028T3 ES07865255T ES07865255T ES2571028T3 ES 2571028 T3 ES2571028 T3 ES 2571028T3 ES 07865255 T ES07865255 T ES 07865255T ES 07865255 T ES07865255 T ES 07865255T ES 2571028 T3 ES2571028 T3 ES 2571028T3
Authority
ES
Spain
Prior art keywords
cr14r15
optionally substituted
nr10r11
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07865255T
Other languages
English (en)
Spanish (es)
Inventor
Georgette Castanedo
Jennafer Dotson
Richard Goldsmith
Janet Gunzner
Tim Heffron
Simon Mathieu
Alan Olivero
Steven Staben
Daniel P Sutherlin
Vickie Tsui
Shumei Wang
Bing-Yan Zhu
Tracy Bayliss
Irina Chuckowree
Adrian FOLKES
Nan Chi Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39403189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2571028(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2571028T3 publication Critical patent/ES2571028T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ES07865255T 2006-12-07 2007-12-05 Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso Active ES2571028T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87342206P 2006-12-07 2006-12-07
PCT/US2007/086533 WO2008073785A2 (en) 2006-12-07 2007-12-05 Phosphoinositide 3-kinase inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
ES2571028T3 true ES2571028T3 (es) 2016-05-23

Family

ID=39403189

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07865255T Active ES2571028T3 (es) 2006-12-07 2007-12-05 Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso

Country Status (19)

Country Link
US (1) US9487533B2 (enExample)
EP (1) EP2114950B1 (enExample)
JP (1) JP5500990B2 (enExample)
KR (1) KR101507182B1 (enExample)
CN (1) CN101675053B (enExample)
AR (1) AR064154A1 (enExample)
AU (1) AU2007333243B2 (enExample)
BR (1) BRPI0717907A2 (enExample)
CA (1) CA2671845C (enExample)
CL (1) CL2007003523A1 (enExample)
ES (1) ES2571028T3 (enExample)
IL (1) IL199151A (enExample)
MX (1) MX2009005925A (enExample)
NO (1) NO342697B1 (enExample)
PE (1) PE20081353A1 (enExample)
RU (1) RU2470936C2 (enExample)
TW (1) TW200829594A (enExample)
WO (1) WO2008073785A2 (enExample)
ZA (1) ZA200904531B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679668B1 (en) * 1996-09-04 2010-01-27 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
EP2158207B1 (en) * 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
CA2699202C (en) * 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5736171B2 (ja) 2007-09-24 2015-06-17 ジェネンテック， インコーポレイテッド チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
UA101676C2 (uk) * 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
EP2344484B1 (en) * 2008-10-17 2016-06-08 Akaal Pharma Pty Ltd S1p receptors modulators and use thereof
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
US8901132B2 (en) * 2009-03-13 2014-12-02 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
US8785651B2 (en) 2009-03-24 2014-07-22 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
US8173650B2 (en) 2009-05-27 2012-05-08 Genentech, Inc. Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
WO2010136491A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2766151A1 (en) * 2009-06-24 2010-12-29 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
JP5546636B2 (ja) 2009-09-28 2014-07-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾキセピンｐｉ３ｋ阻害剤化合物及び使用方法
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
KR101447789B1 (ko) * 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011130628A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
CA2802808A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
JP5766820B2 (ja) 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤としての複素環化合物
EP2683243A4 (en) * 2011-03-09 2014-12-03 Celgene Avilomics Res Inc PI3 KINASE INHIBITORS AND USES THEREOF
MX340013B (es) 2011-03-21 2016-06-22 Hoffmann La Roche Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
PL3111938T3 (pl) * 2011-04-01 2019-09-30 Curis, Inc. Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
CN104053661B (zh) 2011-11-23 2018-06-19 癌症研究技术有限公司 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
KR101698283B1 (ko) 2012-10-10 2017-01-19 에프. 호프만-라 로슈 아게 티에노피리미딘 화합물의 제조 방법
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (en) * 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9708341B2 (en) 2014-06-09 2017-07-18 Sumitomo Chemical Company, Limited Method for producing pyridine compound
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
AU2016287189A1 (en) 2015-06-29 2017-10-12 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
EP3394056B1 (en) * 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018001952A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
EP3573992B1 (en) 2017-01-26 2022-04-13 Youla S. Tsantrizos Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN113164466B (zh) 2018-09-11 2025-07-08 柯瑞斯公司 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US12319686B2 (en) 2019-01-17 2025-06-03 Hoffmann-La Roche Inc. Process for the preparation of tetrahydropyridopyrimidines
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
CN115135659B (zh) * 2021-01-15 2024-03-12 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1959403A1 (de) * 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2050814A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
DE2058085A1 (de) * 1970-11-26 1972-05-31 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US5075305A (en) * 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2423981A1 (en) * 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1773507B1 (en) * 2004-06-03 2012-08-15 Nordson Corporation Color change for powder coating material application system
EP1806347A4 (en) * 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
KR101533461B1 (ko) * 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
PL2041139T3 (pl) * 2006-04-26 2012-05-31 Hoffmann La Roche Związki farmaceutyczne
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso

Also Published As

Publication number Publication date
CA2671845C (en) 2015-03-24
KR101507182B1 (ko) 2015-03-30
AU2007333243A1 (en) 2008-06-19
IL199151A (en) 2017-01-31
WO2008073785A3 (en) 2008-08-28
BRPI0717907A2 (pt) 2013-11-05
AR064154A1 (es) 2009-03-18
CN101675053A (zh) 2010-03-17
NO342697B1 (no) 2018-07-09
EP2114950A2 (en) 2009-11-11
US9487533B2 (en) 2016-11-08
WO2008073785A2 (en) 2008-06-19
CL2007003523A1 (es) 2008-08-22
AU2007333243B2 (en) 2013-03-14
CN101675053B (zh) 2014-03-12
TW200829594A (en) 2008-07-16
NO20092565L (no) 2009-09-07
US20080269210A1 (en) 2008-10-30
JP2010512337A (ja) 2010-04-22
JP5500990B2 (ja) 2014-05-21
CA2671845A1 (en) 2008-06-19
EP2114950B1 (en) 2016-03-09
ZA200904531B (en) 2010-09-29
RU2009125916A (ru) 2011-01-20
MX2009005925A (es) 2009-08-12
PE20081353A1 (es) 2008-11-12
KR20090106508A (ko) 2009-10-09
RU2470936C2 (ru) 2012-12-27
IL199151A0 (en) 2010-03-28

Similar Documents

Publication Publication Date Title
ES2571028T3 (es) Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
ES2548998T3 (es) Composiciones antifúngicas de azol
PE20010632A1 (es) Derivados de ter-butil-(7-metil-imidazol[1,2-a]piridin-3-il)-amina, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
PE20071285A1 (es) Composicion para inducir la tolerancia de plantas contra bacteriosis
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
AR060632A1 (es) Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
AR054814A1 (es) Derivados de piridazina
CO6140061A2 (es) Compuestos de pirazol heterobiciclicos y metodos de uso
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
AR075321A1 (es) Compuestos de amidina sustituida para combatir plagas de animales
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CO5631447A2 (es) Derivados de heteriarilamida benzocondesada de tieno- piridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos, y metodos pra su uso
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
UY31014A1 (es) Derivados de ftalazinona
CO6210770A2 (es) Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5